ClinicalTrials.gg
CompletedNCT01387607Updated Jan 28, 2021Results posted

A Study For Pregabalin In Patients With Fibromyalgia

A Phase 3 interventional study of pregabalin and placebo in Fibromyalgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 22 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing pregabalin in Fibromyalgia — 6 open to participants now, 6 under way, none of them phase 3. Pregabalin · Fibromyalgia.

Enrollment
14th of 30
343 · median 199
Started
2012
the only one that year
Phase 3
13 of 30
none open now
Registered
17th of 30
by date
Lead sponsor
15 of 30
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 30 studies testing pregabalin in Fibromyalgia, this one is the 14th largest by enrollment, is the only one that started in 2012, is one of 13 in phase 3, and was the 17th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

6 of the 30 studies testing pregabalin in Fibromyalgia are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing pregabalin in Fibromyalgia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and tolerability of pregabalin compared with placebo for management of fibromyalgia in adults.

03

Conditions studied

  • Fibromyalgia

Browse trials for

Keywords

  • Pregabalin
  • fibromyalgia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients, at least 18 years of age
  • Meeting the ACR (America College of Rheumatology) criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites)
  • At screening (V1) and randomization (V2), patients must have a score of no less than 40 mm on the Pain Visual Analog Scale (VAS)
  • At randomization (V2), at least 4 pain diaries must be completed satisfactorily within the last 7 days and the average pain score must be no less than 4

Exclusion criteria

Exclusion Criteria:

  • Patients with no less than 30% decrease on the Pain Visual Analog Scale (VAS) at randomization (V2) as compared to screening (V1)
  • Patients with other severe pain due to other conditions (eg, DPN or PHN) that may confound assessment or self-evaluation of the pain associated with fibromyalgia
  • Patients with any widespread inflammatory musculoskeletal disorders, widespread rheumatic diseases other than fibromyalgia, active infections, or untreated endocrine disorders
  • less than 60 mL/min (estimated from serum creatinine)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
343 participants (actual)

Study arms

  • Experimental
    Pregabalin

    Drug: pregabalin

  • Placebo comparator
    Placebo

    Matched placebo

    Drug: placebo

Interventions

  • Pregabalin capsule, 300-450mg/day, twice daily

  • Drugplacebo

    Placebo, twice daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Endpoint Mean Pain Score During the Double-blind Treatment Period at Week 14

    Assessment of mean pain score was based on participant's daily pain diary. The daily pain diary consisted of an 11-point numeric rating scale ranging from 0 (no pain) to 10 (worst possible pain). The participants rated their pain during the past 24 hours by choosing the appropriate number between 0 and 10. Self-assessment was performed daily at awakening. The endpoint mean pain score was defined as the mean of the Week 14 pain diary entries in the double-blind treatment phase. Baseline was defined as the mean of last 7 pain diary entries up to and including Day 1.

    Time frame: Baseline, Week 14

Secondary outcomes

  1. Percentage of Participants Categorized by Each Patient Global Impression of Change (PGIC) Score at Week 14

    The Patient Global Impression of Change (PGIC) was a participant-rated instrument that measured change in participant's overall status on a scale ranging from 1 (very much improved) to 7 (very much worse), which was based on a validated scale, the Clinical Global Impression of Change (CGIC). Categories were defined based on the PGIC scores as followed: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse and 7 = very much worse.

    Time frame: Week 14

  2. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Score at Week 14

    The Fibromyalgia Impact Questionnaire (FIQ) was a 20-item participant-reported outcome instrument designed to assess health status, progress, and outcomes in participants with fibromyalgia. It contained 10 subscales. There were 11 questions that are related specifically to physical functioning. The remaining items assessed pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. Score range for each subscale was 0 to 10. The 10 subscales were combined to yield a total score with range from 0 to 100. The total score provided an estimation of fibromyalgia impact with higher scores indicating greater impairment.

    Time frame: Baseline, Week 14

  3. Percentage of Participants With at Least 30% Reduction in Weekly Mean Pain Score From Baseline to Week 14

    Assessment of mean pain score was based on participant's daily pain diary. The daily pain diary consisted of an 11-point numeric rating scale ranging from 0 (no pain) to 10 (worst possible pain). The participants rated their pain during the past 24 hours by choosing the appropriate number between 0 and 10. Self-assessment was performed daily at awakening. Weekly mean pain score was calculated as mean value of the observations within the window for each week during the double-blind treatment phase. A participant with at least 30% reduction in weekly mean pain score from baseline to Week 14 was defined as a 30% responder.

    Time frame: Baseline, Week 14

  4. Percentage of Participants With at Least 50% Reduction in Weekly Mean Pain Score From Baseline to Week 14

    Assessment of mean pain score was based on participant's daily pain diary. The daily pain diary consisted of an 11-point numeric rating scale ranging from 0 (no pain) to 10 (worst possible pain). The participants rated their pain during the past 24 hours by choosing the appropriate number between 0 and 10. Self-assessment was performed daily at awakening. Weekly mean pain score was calculated as mean value of the observations within the window for each week during the double-blind treatment phase. A participant with at least 50% reduction in weekly mean pain score from baseline to Week 14 was defined as a 50% responder.

    Time frame: Baseline, Week 14

  5. Change From Baseline at Week 14 in Medical Outcome Study (MOS)-Sleep Scale - Sleep Disturbance Subscale Score

    The Medical Outcomes Study (MOS)-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. Range of scores represented for sleep disturbance was 0 to 100, with higher scores indicating more of the attribute.

    Time frame: Baseline, Week 14

  6. Change From Baseline at Week 14 in Medical Outcome Study (MOS)-Sleep Scale - Snoring, Awaken Short of Breath and Sleep Adequacy Subscale Scores

    The Medical Outcomes Study (MOS)-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. Range of scores represented for snoring, awaken short of breath and sleep adequacy was 0 to 100, with higher scores indicating more of the attribute.

    Time frame: Baseline, Week 14

  7. Change From Baseline at Week 14 in Medical Outcome Study (MOS)-Sleep Scale - Quantity of Sleep and Somnolence Subscale Scores

    The Medical Outcomes Study (MOS)-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. Range of quantity of sleep parameter was 0 to 24 and somnolence was 0 to 100, with higher scores indicating more of the attribute.

    Time frame: Baseline, Week 14

  8. Change From Baseline at Week 14 in Medical Outcome Study (MOS)-Sleep Scale - Sleep Problems Index Overall Score

    The Medical Outcomes Study (MOS)-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. Range of sleep problem index overall score was 0 to 100, with higher scores indicating more of the attribute.

    Time frame: Baseline, Week 14

  9. Percentage of Participants With Optimal Sleep at Week 14 in Medical Outcome Study (MOS)-Sleep Scale

    The Medical Outcomes Study (MOS)-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index.

    Time frame: Baseline, Week 14

  10. Change From Baseline in Mean Sleep Interference Score at Week 14

    The Daily Sleep Interference Scale was an 11-point numerical scale ranging from 0 (does not interfere with sleep) to 10 (completely interferes \[unable to sleep due to pain\]). Participants were asked to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10. Self-assessment was performed daily upon awakening. Baseline Mean Sleep Interference score was defined as the mean of all available last 7 sleep interference score diary entries up to and including Day 1.

    Time frame: Baseline, Week 14

  11. Change From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Subjective Wake After Sleep Onset (sWASO)

    The Subjective Sleep Questionnaire (SSQ) was included in the participant's diary and designed to capture subjective evaluation of sleep behavior in participants with disrupted sleep. It was administered to each participant approximately 30 - 60 minutes after arising each day in the morning. The Subjective Wake after Sleep Onset (sWASO) parameter subjectively estimated the total amount of time the participant was awake after initial sleep onset until final awakening. Baseline was defined as the mean of last 7 SSQ diary entries up to and including Day 1.

    Time frame: Baseline, Week 14

  12. Change From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Subjective Latency to Sleep Onset (sLSO)

    The Subjective Sleep Questionnaire (SSQ) was included in the participant's diary and designed to capture subjective evaluation of sleep behavior in participants with disrupted sleep. It was administered to each participant approximately 30 - 60 minutes after arising each day in the morning. The Subjective Latency to Sleep Onset (sLSO) parameter subjectively estimated the amount of time to fall asleep after lights out. Baseline was defined as the mean of last 7 SSQ diary entries up to and including Day 1.

    Time frame: Baseline, Week 14

  13. Change From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Subjective Number of Awakenings After Sleep Onset (sNAASO)

    The Subjective Sleep Questionnaire (SSQ) was included in the participant's diary and designed to capture subjective evaluation of sleep behavior in participants with disrupted sleep. It was administered to each participant approximately 30 - 60 minutes after arising each day in the morning. The Subjective Number of Awakenings after Sleep Onset (sNAASO) parameter subjectively estimated the total number of times the participant awakened during the night until final awakening. Baseline was defined as the mean of last 7 SSQ diary entries up to and including Day 1.

    Time frame: Baseline, Week 14

  14. Change From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Subjective Total Sleep Time (sTST)

    The Subjective Sleep Questionnaire (SSQ) was included in the participant's diary and designed to capture subjective evaluation of sleep behavior in participants with disrupted sleep. It was administered to each participant approximately 30 - 60 minutes after arising each day in the morning. The Subjective Total Sleep Time (sTST) parameter subjectively estimated the total amount of time the participant was asleep after lights out until final awakening. Baseline was defined as the mean of last 7 SSQ diary entries up to and including Day 1.

    Time frame: Baseline, Week 14

  15. Change From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Sleep Quality

    The Subjective Sleep Questionnaire (SSQ) was included in the participant's diary and designed to capture subjective evaluation of sleep behavior in participants with disrupted sleep. It was administered to each participant approximately 30 - 60 minutes after arising each day in the morning. The Sleep Quality parameter subjectively rated the quality of sleep during the past night by selecting a number between 0 (very poor) and 10 (excellent). Baseline was defined as the mean of last 7 SSQ diary entries up to and including Day 1.

    Time frame: Baseline, Week 14

  16. Change From Baseline in Multidimensional Assessment of Fatigue (MAF) Score at Week 14

    The Multidimensional Assessment of Fatigue (MAF) scale was a self-administered survey that yielded a Global Fatigue Index by assessing the participant's level of fatigue and the degree to which fatigue interferes with activities of daily living. It contained 16 items and measured 4 dimensions of fatigue: severity (2 items), distress (1 item), degree of interference in activities of daily living (11 items), and timing (2 items). Index range was 1 to 50 and higher scores reflected greater impairment.

    Time frame: Baseline, Week 14

  17. Change From Baseline at Week 14 in Short-Form 36 (SF-36) Health Survey - Mental Component Summary Score

    The Short-Form 36 Health Survey (SF-36) was a self-administered questionnaire that measured each of the following 8 health concepts: Physical functioning, role limitations due to physical problems, social functioning, bodily pain, mental health, role limitations due to emotional problems, vitality, and general health perception. Mental component included mental health, role limitations due to emotional problems, vitality and general health perception. Score range for mental component summary score was 0 to 100 and higher scores reflected better participant status.

    Time frame: Baseline, Week 14

  18. Change From Baseline at Week 14 in Short-Form 36 (SF-36) Health Survey - Physical Component Summary Score

    The Short-Form 36 Health Survey (SF-36) was a self-administered questionnaire that measured each of the following 8 health concepts: Physical functioning, role limitations due to physical problems, social functioning, bodily pain, mental health, role limitations due to emotional problems, vitality, and general health perception. Physical component included physical functioning, role limitations due to physical problems, social functioning and bodily pain. Score range for physical component summary score was 0 to 100 and higher scores reflected better participant status.

    Time frame: Baseline, Week 14

  19. Change From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Week 14

    The Pain Visual Analog Scale (Pain VAS) was a horizontal line; 100 mm in length, self administered by the participants in order to rate pain from 0 "no pain" to 100 "worst possible pain".

    Time frame: Baseline, Week 14

  20. Change From Baseline at Week 14 in Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale Score

    The Hospital Anxiety and Depression Scale (HADS) was a self-reported 14-item instrument that consisted of two 7-item subscales that measure the presence and severity of anxiety and depression. For each subscale, score range was 0 to 21, with higher scores indicating greater impairment.

    Time frame: Baseline, Week 14

  21. Change From Baseline at Week 14 in Hospital Anxiety and Depression Scale (HADS) - Depression Subscale Score

    The Hospital Anxiety and Depression Scale (HADS) was a self-reported 14-item instrument that consisted of two 7-item subscales that measure the presence and severity of anxiety and depression. For each subscale, range was 0 to 21, with higher scores indicating greater impairment.

    Time frame: Baseline, Week 14

  22. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device. A Serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect. Treatment-emergent AEs (TEAEs) were events between first dose of study drug and up to follow-up visit (Study Day 105) that were absent before treatment or that worsened after treatment. AEs included both SAEs and non-SAEs.

    Time frame: Baseline to Follow up (Day 105)

  23. Number of Treatment-Emergent Adverse Events (TEAEs) Categorized by Severity

    A mild Adverse Event (AE) was an AE that did not interfere with participant's usual function. A moderate AE was an AE that interfered participant's usual function to some extent. A severe AE was an AE that interfered significantly with participant's usual function.

    Time frame: Baseline to Follow up (Day 105)

07

Results

Posted Jul 30, 2018

Participant flow

Participant flow — Overall Study
MilestonePregabalinPlacebo
Started173170
Received treatment170164
Completed122125
Not completed5145
Withdrew: Adverse event2311
Withdrew: Lack of efficacy86
Withdrew: Lost to follow-up21
Withdrew: No longer meets eligibility criteria01
Withdrew: Protocol violation15
Withdrew: Withdrawal by subject1314
Withdrew: Other11
Withdrew: Randomized, not treated36

Outcome measures

PrimaryChange From Baseline in Endpoint Mean Pain Score During the Double-blind Treatment Period at Week 14

Assessment of mean pain score was based on participant's daily pain diary. The daily pain diary consisted of an 11-point numeric rating scale ranging from 0 (no pain) to 10 (worst possible pain). The participants rated their pain during the past 24 hours by choosing the appropriate number between 0 and 10. Self-assessment was performed daily at awakening. The endpoint mean pain score was defined as the mean of the Week 14 pain diary entries in the double-blind treatment phase. Baseline was defined as the mean of last 7 pain diary entries up to and including Day 1.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Endpoint Mean Pain Score During the Double-blind Treatment Period at Week 14
Units on a scalePregabalinPlacebo
Change From Baseline in Endpoint Mean Pain Score During the Double-blind Treatment Period at Week 14-2.01 ± 0.148-1.28 ± 0.150
Statistical analysis
  • Pregabalin vs Placebo · Mixed-effects model repeated measures · p = 0.0001 (From a repeated measures analysis (MMRM) with treatment, pooled center, week, and treatment-by-week interaction as factors, and baseline value as covariate.) · Mean difference (final values): -0.730 · 95% CI -1.10 to -0.36
SecondaryPercentage of Participants Categorized by Each Patient Global Impression of Change (PGIC) Score at Week 14

The Patient Global Impression of Change (PGIC) was a participant-rated instrument that measured change in participant's overall status on a scale ranging from 1 (very much improved) to 7 (very much worse), which was based on a validated scale, the Clinical Global Impression of Change (CGIC). Categories were defined based on the PGIC scores as followed: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse and 7 = very much worse.

Time frame:
Week 14
Reported as:
Number · Percentage of participants
Percentage of Participants Categorized by Each Patient Global Impression of Change (PGIC) Score at Week 14
Percentage of participantsPregabalinPlacebo
Very much improved9.97.7
Much improved25.419.7
Minimally improved40.142.3
No change17.624.6
Minimally worse4.93.5
Much worse2.12.1
Very much worse0.00.0
Statistical analysis
  • Pregabalin vs Placebo · Cochran-Mantel-Haenszel · p = 0.1397 (Based on the combined categories from Cochran-Mantel-Haenszel test adjusted for pooled center.) · Odds ratio (or): 1.4376 · 95% CI 0.8732 to 2.3667Overall odds ratio was calculated based on Mentel-Haenszel method as pregabalin versus placebo.
  • Pregabalin vs Placebo · Cochran-Mantel-Haenszel · p = 0.1510 (Based on the combined categories from Cochran-Mantel-Haenszel test adjusted for pooled center.) · Odds ratio (or): 1.4626 · 95% CI 0.8596 to 2.4886Overall odds ratio was calculated based on Mentel-Haenszel method as pregabalin versus placebo.
SecondaryChange From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Score at Week 14

The Fibromyalgia Impact Questionnaire (FIQ) was a 20-item participant-reported outcome instrument designed to assess health status, progress, and outcomes in participants with fibromyalgia. It contained 10 subscales. There were 11 questions that are related specifically to physical functioning. The remaining items assessed pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. Score range for each subscale was 0 to 10. The 10 subscales were combined to yield a total score with range from 0 to 100. The total score provided an estimation of fibromyalgia impact with higher scores indicating greater impairment.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Score at Week 14
Units on a scalePregabalinPlacebo
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Score at Week 14-11.14 ± 1.343-8.15 ± 1.367
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.0762 (From the analysis of covariate (ANCOVA) with treatment and pooled center as factors, and baseline value as covariate.) · Mean difference (final values): -2.990 · 95% CI -6.30 to 0.32
SecondaryPercentage of Participants With at Least 30% Reduction in Weekly Mean Pain Score From Baseline to Week 14

Assessment of mean pain score was based on participant's daily pain diary. The daily pain diary consisted of an 11-point numeric rating scale ranging from 0 (no pain) to 10 (worst possible pain). The participants rated their pain during the past 24 hours by choosing the appropriate number between 0 and 10. Self-assessment was performed daily at awakening. Weekly mean pain score was calculated as mean value of the observations within the window for each week during the double-blind treatment phase. A participant with at least 30% reduction in weekly mean pain score from baseline to Week 14 was defined as a 30% responder.

Time frame:
Baseline, Week 14
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 30% Reduction in Weekly Mean Pain Score From Baseline to Week 14
Percentage of participantsPregabalinPlacebo
Percentage of Participants With at Least 30% Reduction in Weekly Mean Pain Score From Baseline to Week 1447.532.7
Statistical analysis
  • Pregabalin vs Placebo · Cochran-Mantel-Haenszel · p = 0.0044 (From Cochran-Mantel-Haenszel test comparing pregabalin to placebo adjusted for pooled center.) · Odds ratio (or): 1.8924 · 95% CI 1.2007 to 2.9827Overall odds ratio was calculated based on Mantel-Haenszel method as pregabalin versus placebo.
SecondaryPercentage of Participants With at Least 50% Reduction in Weekly Mean Pain Score From Baseline to Week 14

Assessment of mean pain score was based on participant's daily pain diary. The daily pain diary consisted of an 11-point numeric rating scale ranging from 0 (no pain) to 10 (worst possible pain). The participants rated their pain during the past 24 hours by choosing the appropriate number between 0 and 10. Self-assessment was performed daily at awakening. Weekly mean pain score was calculated as mean value of the observations within the window for each week during the double-blind treatment phase. A participant with at least 50% reduction in weekly mean pain score from baseline to Week 14 was defined as a 50% responder.

Time frame:
Baseline, Week 14
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 50% Reduction in Weekly Mean Pain Score From Baseline to Week 14
Percentage of participantsPregabalinPlacebo
Percentage of Participants With at Least 50% Reduction in Weekly Mean Pain Score From Baseline to Week 1427.217.0
Statistical analysis
  • Pregabalin vs Placebo · Cochran-Mantel-Haenszel · p = 0.0189 (From Cochran-Mantel-Haenszel test comparing pregabalin to placebo adjusted for pooled center.) · Odds ratio (or): 1.9683 · 95% CI 1.1151 to 3.4742Overall odds ratio was calculated based on Mantel-Haenszel method as pregabalin versus placebo.
SecondaryChange From Baseline at Week 14 in Medical Outcome Study (MOS)-Sleep Scale - Sleep Disturbance Subscale Score

The Medical Outcomes Study (MOS)-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. Range of scores represented for sleep disturbance was 0 to 100, with higher scores indicating more of the attribute.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Units on a scale
Change From Baseline at Week 14 in Medical Outcome Study (MOS)-Sleep Scale - Sleep Disturbance Subscale Score
Units on a scalePregabalinPlacebo
Change From Baseline at Week 14 in Medical Outcome Study (MOS)-Sleep Scale - Sleep Disturbance Subscale Score-11.45 ± 1.608-8.02 ± 1.636
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.0900 (From the analysis of covariance (ANCOVA) with treatment and pooled center as factors and baseline value as covariate.) · Mean difference (final values): -3.427 · 95% CI -7.39 to 0.54
SecondaryChange From Baseline at Week 14 in Medical Outcome Study (MOS)-Sleep Scale - Snoring, Awaken Short of Breath and Sleep Adequacy Subscale Scores

The Medical Outcomes Study (MOS)-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. Range of scores represented for snoring, awaken short of breath and sleep adequacy was 0 to 100, with higher scores indicating more of the attribute.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Units on a scale
Change From Baseline at Week 14 in Medical Outcome Study (MOS)-Sleep Scale - Snoring, Awaken Short of Breath and Sleep Adequacy Subscale Scores
Units on a scalePregabalinPlacebo
Snoring4.61 ± 1.7482.08 ± 1.777
Awaken Short of Breath-6.76 ± 1.809-4.41 ± 1.842
Sleep Adequacy14.23 ± 1.9405.20 ± 1.990
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.2485 (From the analysis of covariance (ANCOVA) with treatment and pooled center as factors and baseline value as covariate.) · Mean difference (final values): 2.527 · 95% CI -1.77 to 6.83
  • Pregabalin vs Placebo · ANCOVA · p = 0.2993 (From the analysis of covariance (ANCOVA) with treatment and pooled center as factors and baseline value as covariate.) · Mean difference (final values): -2.355 · 95% CI -6.81 to 2.10
  • Pregabalin vs Placebo · ANCOVA · p = 0.0003 (From the analysis of covariance (ANCOVA) with treatment and pooled center as factors and baseline value as covariate.) · Mean difference (final values): 9.030 · 95% CI 4.21 to 13.85
SecondaryChange From Baseline at Week 14 in Medical Outcome Study (MOS)-Sleep Scale - Quantity of Sleep and Somnolence Subscale Scores

The Medical Outcomes Study (MOS)-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. Range of quantity of sleep parameter was 0 to 24 and somnolence was 0 to 100, with higher scores indicating more of the attribute.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Units on a scale
Change From Baseline at Week 14 in Medical Outcome Study (MOS)-Sleep Scale - Quantity of Sleep and Somnolence Subscale Scores
Units on a scalePregabalinPlacebo
Quantity of Sleep0.61 ± 0.0890.32 ± 0.090
Somnolence-1.29 ± 1.311-5.48 ± 1.337
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.0106 (From the analysis of covariance (ANCOVA) with treatment and pooled center as factors and baseline value as covariate.) · Mean difference (final values): 0.286 · 95% CI 0.07 to 0.51
  • Pregabalin vs Placebo · ANCOVA · p = 0.0112 (From the analysis of covariance (ANCOVA) with treatment and pooled center as factors and baseline value as covariate.) · Mean difference (final values): 4.194 · 95% CI 0.96 to 7.43
SecondaryChange From Baseline at Week 14 in Medical Outcome Study (MOS)-Sleep Scale - Sleep Problems Index Overall Score

The Medical Outcomes Study (MOS)-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. Range of sleep problem index overall score was 0 to 100, with higher scores indicating more of the attribute.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Units on a scale
Change From Baseline at Week 14 in Medical Outcome Study (MOS)-Sleep Scale - Sleep Problems Index Overall Score
Units on a scalePregabalinPlacebo
Change From Baseline at Week 14 in Medical Outcome Study (MOS)-Sleep Scale - Sleep Problems Index Overall Score-9.70 ± 1.307-6.64 ± 1.334
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.0637 (From the analysis of covariance (ANCOVA) with treatment and pooled center as factors and baseline value as covariate.) · Mean difference (final values): -3.059 · 95% CI -6.29 to 0.18
SecondaryPercentage of Participants With Optimal Sleep at Week 14 in Medical Outcome Study (MOS)-Sleep Scale

The Medical Outcomes Study (MOS)-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index.

Time frame:
Baseline, Week 14
Reported as:
Number · Percentage of participants
Percentage of Participants With Optimal Sleep at Week 14 in Medical Outcome Study (MOS)-Sleep Scale
Percentage of participantsPregabalinPlacebo
Percentage of Participants With Optimal Sleep at Week 14 in Medical Outcome Study (MOS)-Sleep Scale41.2 ± 41.243.6 ± 43.6
Statistical analysis
  • Pregabalin vs Placebo · Regression, Logistic · p = 0.6767 (Logistic regression model includes treatment and pooled center as factors and baseline value as covariate.) · Odds ratio (or): 1.12 · 95% CI 0.67 to 1.87
SecondaryChange From Baseline in Mean Sleep Interference Score at Week 14

The Daily Sleep Interference Scale was an 11-point numerical scale ranging from 0 (does not interfere with sleep) to 10 (completely interferes \[unable to sleep due to pain\]). Participants were asked to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10. Self-assessment was performed daily upon awakening. Baseline Mean Sleep Interference score was defined as the mean of all available last 7 sleep interference score diary entries up to and including Day 1.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Mean Sleep Interference Score at Week 14
Units on a scalePregabalinPlacebo
Change From Baseline in Mean Sleep Interference Score at Week 14-1.88 ± 0.150-1.00 ± 0.153
Statistical analysis
  • Pregabalin vs Placebo · Mixed-effects model repeated measures · p = <0.0001 (From a repeated measures analysis (MMRM) with treatment, pooled center, week, and treatment-by-week interaction as factors, and baseline value as covariate.) · Mean difference (final values): -0.882 · 95% CI -1.26 to -0.50
SecondaryChange From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Subjective Wake After Sleep Onset (sWASO)

The Subjective Sleep Questionnaire (SSQ) was included in the participant's diary and designed to capture subjective evaluation of sleep behavior in participants with disrupted sleep. It was administered to each participant approximately 30 - 60 minutes after arising each day in the morning. The Subjective Wake after Sleep Onset (sWASO) parameter subjectively estimated the total amount of time the participant was awake after initial sleep onset until final awakening. Baseline was defined as the mean of last 7 SSQ diary entries up to and including Day 1.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Minutes
Change From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Subjective Wake After Sleep Onset (sWASO)
MinutesPregabalinPlacebo
Change From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Subjective Wake After Sleep Onset (sWASO)-42.36 ± 5.920-25.19 ± 6.010
Statistical analysis
  • Pregabalin vs Placebo · Mixed-effects model repeated measures · p = 0.0273 (From a repeated measures analysis (MMRM) with treatment, pooled center, week, and treatment-by-week interaction as factors, and baseline value as covariate.) · Mean difference (final values): -17.172 · 95% CI -32.42 to -1.92
SecondaryChange From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Subjective Latency to Sleep Onset (sLSO)

The Subjective Sleep Questionnaire (SSQ) was included in the participant's diary and designed to capture subjective evaluation of sleep behavior in participants with disrupted sleep. It was administered to each participant approximately 30 - 60 minutes after arising each day in the morning. The Subjective Latency to Sleep Onset (sLSO) parameter subjectively estimated the amount of time to fall asleep after lights out. Baseline was defined as the mean of last 7 SSQ diary entries up to and including Day 1.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Minutes
Change From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Subjective Latency to Sleep Onset (sLSO)
MinutesPregabalinPlacebo
Change From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Subjective Latency to Sleep Onset (sLSO)-0.26 ± 0.052-0.28 ± 0.053
Statistical analysis
  • Pregabalin vs Placebo · Mixed-effects model repeated measures · p = 0.8082 (From a repeated measures analysis (MMRM) with treatment, pooled center, week, and treatment-by-week interaction as factors, and baseline value as covariate.) · Mean difference (final values): 0.016 · 95% CI -0.12 to 0.15
SecondaryChange From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Subjective Number of Awakenings After Sleep Onset (sNAASO)

The Subjective Sleep Questionnaire (SSQ) was included in the participant's diary and designed to capture subjective evaluation of sleep behavior in participants with disrupted sleep. It was administered to each participant approximately 30 - 60 minutes after arising each day in the morning. The Subjective Number of Awakenings after Sleep Onset (sNAASO) parameter subjectively estimated the total number of times the participant awakened during the night until final awakening. Baseline was defined as the mean of last 7 SSQ diary entries up to and including Day 1.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Awakenings
Change From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Subjective Number of Awakenings After Sleep Onset (sNAASO)
AwakeningsPregabalinPlacebo
Change From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Subjective Number of Awakenings After Sleep Onset (sNAASO)-0.95 ± 0.094-0.30 ± 0.095
Statistical analysis
  • Pregabalin vs Placebo · Mixed-effects model repeated measures · p = <0.0001 (From a repeated measures analysis (MMRM) with treatment, pooled center, week, and treatment-by-week interaction as factors, and baseline value as covariate.) · Mean difference (final values): -0.655 · 95% CI -0.89 to -0.41
SecondaryChange From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Subjective Total Sleep Time (sTST)

The Subjective Sleep Questionnaire (SSQ) was included in the participant's diary and designed to capture subjective evaluation of sleep behavior in participants with disrupted sleep. It was administered to each participant approximately 30 - 60 minutes after arising each day in the morning. The Subjective Total Sleep Time (sTST) parameter subjectively estimated the total amount of time the participant was asleep after lights out until final awakening. Baseline was defined as the mean of last 7 SSQ diary entries up to and including Day 1.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Minutes
Change From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Subjective Total Sleep Time (sTST)
MinutesPregabalinPlacebo
Change From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Subjective Total Sleep Time (sTST)24.63 ± 5.85117.23 ± 5.958
Statistical analysis
  • Pregabalin vs Placebo · Mixed-effects model repeated measures · p = 0.3388 (From a repeated measures analysis (MMRM) with treatment, pooled center, week, and treatment-by-week interaction as factors, and baseline value as covariate.) · Mean difference (final values): 7.396 · 95% CI -7.76 to 22.55
SecondaryChange From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Sleep Quality

The Subjective Sleep Questionnaire (SSQ) was included in the participant's diary and designed to capture subjective evaluation of sleep behavior in participants with disrupted sleep. It was administered to each participant approximately 30 - 60 minutes after arising each day in the morning. The Sleep Quality parameter subjectively rated the quality of sleep during the past night by selecting a number between 0 (very poor) and 10 (excellent). Baseline was defined as the mean of last 7 SSQ diary entries up to and including Day 1.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Units on a scale
Change From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Sleep Quality
Units on a scalePregabalinPlacebo
Change From Baseline at Week 14 in Subjective Sleep Questionnaire (SSQ) - Sleep Quality1.59 ± 0.1660.82 ± 0.169
Statistical analysis
  • Pregabalin vs Placebo · Mixed-effects model repeated measures · p = 0.0003 (From a repeated measures analysis (MMRM) with treatment, pooled center, week, and treatment-by-week interaction as factors, and baseline value as covariate.) · Mean difference (final values): 0.765 · 95% CI 0.35 to 1.18
SecondaryChange From Baseline in Multidimensional Assessment of Fatigue (MAF) Score at Week 14

The Multidimensional Assessment of Fatigue (MAF) scale was a self-administered survey that yielded a Global Fatigue Index by assessing the participant's level of fatigue and the degree to which fatigue interferes with activities of daily living. It contained 16 items and measured 4 dimensions of fatigue: severity (2 items), distress (1 item), degree of interference in activities of daily living (11 items), and timing (2 items). Index range was 1 to 50 and higher scores reflected greater impairment.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Multidimensional Assessment of Fatigue (MAF) Score at Week 14
Units on a scalePregabalinPlacebo
Change From Baseline in Multidimensional Assessment of Fatigue (MAF) Score at Week 14-4.09 ± 0.676-3.25 ± 0.681
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.3186 (From the analysis of covariate (ANCOVA) with treatment and pooled center as factors, and baseline value as covariate.) · Mean difference (final values): -0.840 · 95% CI -2.50 to 0.82
SecondaryChange From Baseline at Week 14 in Short-Form 36 (SF-36) Health Survey - Mental Component Summary Score

The Short-Form 36 Health Survey (SF-36) was a self-administered questionnaire that measured each of the following 8 health concepts: Physical functioning, role limitations due to physical problems, social functioning, bodily pain, mental health, role limitations due to emotional problems, vitality, and general health perception. Mental component included mental health, role limitations due to emotional problems, vitality and general health perception. Score range for mental component summary score was 0 to 100 and higher scores reflected better participant status.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Units on a scale
Change From Baseline at Week 14 in Short-Form 36 (SF-36) Health Survey - Mental Component Summary Score
Units on a scalePregabalinPlacebo
Change From Baseline at Week 14 in Short-Form 36 (SF-36) Health Survey - Mental Component Summary Score2.68 ± 0.8312.30 ± 0.846
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.7149 (From the analysis of covariate (ANCOVA) with treatment and pooled center as factors, and baseline value as covariate.) · Mean difference (final values): 0.380 · 95% CI -1.67 to 2.43
SecondaryChange From Baseline at Week 14 in Short-Form 36 (SF-36) Health Survey - Physical Component Summary Score

The Short-Form 36 Health Survey (SF-36) was a self-administered questionnaire that measured each of the following 8 health concepts: Physical functioning, role limitations due to physical problems, social functioning, bodily pain, mental health, role limitations due to emotional problems, vitality, and general health perception. Physical component included physical functioning, role limitations due to physical problems, social functioning and bodily pain. Score range for physical component summary score was 0 to 100 and higher scores reflected better participant status.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Units on a scale
Change From Baseline at Week 14 in Short-Form 36 (SF-36) Health Survey - Physical Component Summary Score
Units on a scalePregabalinPlacebo
Change From Baseline at Week 14 in Short-Form 36 (SF-36) Health Survey - Physical Component Summary Score4.44 ± 0.5383.66 ± 0.548
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.2442 (From the analysis of covariate (ANCOVA) with treatment and pooled center as factors, and baseline value as covariate.) · Mean difference (final values): 0.785 · 95% CI -0.54 to 2.11
SecondaryChange From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Week 14

The Pain Visual Analog Scale (Pain VAS) was a horizontal line; 100 mm in length, self administered by the participants in order to rate pain from 0 "no pain" to 100 "worst possible pain".

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Week 14
Units on a scalePregabalinPlacebo
Change From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Week 14-17.04 ± 1.922-13.43 ± 1.952
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.1332 (From the analysis of covariate (ANCOVA) with treatment and pooled center as factors, and baseline value as covariate.) · Mean difference (final values): -3.616 · 95% CI -8.34 to 1.11
SecondaryChange From Baseline at Week 14 in Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale Score

The Hospital Anxiety and Depression Scale (HADS) was a self-reported 14-item instrument that consisted of two 7-item subscales that measure the presence and severity of anxiety and depression. For each subscale, score range was 0 to 21, with higher scores indicating greater impairment.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Units on a scale
Change From Baseline at Week 14 in Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale Score
Units on a scalePregabalinPlacebo
Change From Baseline at Week 14 in Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale Score-1.03 ± 0.287-0.65 ± 0.292
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.2934 (From the analysis of covariate (ANCOVA) with treatment and pooled center as factors, and baseline value as covariate.) · Mean difference (final values): -0.378 · 95% CI -1.09 to 0.33
SecondaryChange From Baseline at Week 14 in Hospital Anxiety and Depression Scale (HADS) - Depression Subscale Score

The Hospital Anxiety and Depression Scale (HADS) was a self-reported 14-item instrument that consisted of two 7-item subscales that measure the presence and severity of anxiety and depression. For each subscale, range was 0 to 21, with higher scores indicating greater impairment.

Time frame:
Baseline, Week 14
Reported as:
Least squares mean · Units on a scale
Change From Baseline at Week 14 in Hospital Anxiety and Depression Scale (HADS) - Depression Subscale Score
Units on a scalePregabalinPlacebo
Change From Baseline at Week 14 in Hospital Anxiety and Depression Scale (HADS) - Depression Subscale Score-1.11 ± 0.290-0.28 ± 0.294
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.0226 (From the analysis of covariate (ANCOVA) with treatment and pooled center as factors, and baseline value as covariate.) · Mean difference (final values): -0.830 · 95% CI -1.54 to -0.12
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device. A Serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect. Treatment-emergent AEs (TEAEs) were events between first dose of study drug and up to follow-up visit (Study Day 105) that were absent before treatment or that worsened after treatment. AEs included both SAEs and non-SAEs.

Time frame:
Baseline to Follow up (Day 105)
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs
ParticipantsPregabalinPlacebo
AEs119103
SAEs09
Discontinuation due to AEs2211
SecondaryNumber of Treatment-Emergent Adverse Events (TEAEs) Categorized by Severity

A mild Adverse Event (AE) was an AE that did not interfere with participant's usual function. A moderate AE was an AE that interfered participant's usual function to some extent. A severe AE was an AE that interfered significantly with participant's usual function.

Time frame:
Baseline to Follow up (Day 105)
Reported as:
Number · Events
Number of Treatment-Emergent Adverse Events (TEAEs) Categorized by Severity
EventsPregabalinPlacebo
Mild AEs183162
Moderate AEs5230
Severe AEs3825

Adverse events

Collected over Baseline to Follow up (Day 105). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—0/170 (0%)88/170 (51.8%)
Placebo—9/164 (5.5%)47/164 (28.7%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPregabalinPlacebo
Atrial tachycardiaCardiac disorders0/1701/164
GoitreEndocrine disorders0/1701/164
Bile duct stoneHepatobiliary disorders0/1701/164
Biliary tract infectionInfections and infestations0/1701/164
Tibia fractureInjury, poisoning and procedural complications0/1701/164
ArthritisMusculoskeletal and connective tissue disorders0/1701/164
FibromyalgiaMusculoskeletal and connective tissue disorders0/1701/164
Cerebral haemangiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1701/164
Cerebral haemorrhageNervous system disorders0/1701/164
Vaginal haemorrhageReproductive system and breast disorders0/1701/164
Most frequent other events
Most frequent other events
EventPregabalinPlacebo
DizzinessNervous system disorders71/17030/164
SomnolenceNervous system disorders30/17013/164
HeadacheNervous system disorders10/17010/164
Upper respiratory tract infectionInfections and infestations10/1707/164

Baseline characteristics

The Full Analysis Set (FAS) was defined as all randomized participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)PregabalinPlaceboTotal
Mean44.5 ± 11.543.5 ± 10.644.0 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)PregabalinPlaceboTotal
Female142144286
Male282048
Primary Diagnoses and Durations
Primary Diagnoses and Durations(years)PregabalinPlaceboTotal
Fibromyalgia duration since onset of symptoms6.0 ± 7.05.6 ± 6.45.8 ± 6.7
Fibromyalgia duration since diagnosis0.3 ± 1.00.4 ± 1.20.3 ± 1.1
08

Study locations

22 sites
  • Department of Rheumatism And Immunity, The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233000, China
  • Anhui Province Hospital
    Hefei, Anhui 230001, China
  • Beijing Chao-Yang Hospital, Capital Medical University
    Beijing, Beijing 100020, China
  • Southwest Hospital of the Third Military Medical University,PLA
    Chongqing, Chongqing 400038, China
  • Department of Neurology,General Hospital of Guangzhou Military Command of PLA
    Guangzhou, Guangdong 510010, China
  • Guangdong General Hospital
    Guangzhou, Guangdong 510080, China
  • Department of Neurology,The First Affiliated Hospital Of Guangzhou Medical University
    Guangzhou, Guangdong 510120, China
  • The Third Affiliated Hospital Of Sun Yat-sen University
    Guangzhou, Guangdong 510630, China
  • Rheumatology Department, The first Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • Rheumatology Department, The second Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150086, China
  • Xiangya Hospital of Centre-south University
    Changsha, Kaifu District, Hunan 410008, China
  • The Second Affiliated Hospital to Nanchang University
    Nanchang, Jiangxi 330006, China
  • Zhongshan Hospital Fudan University, Rheumatology Department
    Shanghai, Shanghai 200032, China
  • Xijing Hospital, The Fourth Military Medical University
    Xi'an, Shanxi 710032, China
  • Si Chuan Huaxi Hospital/Rheumatology Department
    Chengdu, Sichuan 610041, China
  • The First Affiliated Hospital of Kunming Medical University/ Rheumatology and Immunology Department
    Kunming, Yunnan 650032, China
  • The First Affiliated Hospital of Wenzhou Medical University/Neurology Department
    Wenzhou, Zhejiang 325000, China
  • China-Japan Friendship Hospital/Rheumatology Department
    Beijing, 100029, China
  • Peking Union Medical College Hospital/Rheumatology Department
    Beijing, 100032, China
  • PLA. The Military General Hospital of Beijing
    Beijing, 100700, China
  • Rheumatology and Immunology Dept., Renji Hospital Shanghai Jiao Tong University School of Medicine
    Shanghai, 200001, China
  • Rheumatology and Immunology Department, Shanghai Changzheng Hospital
    Shanghai, 200003, China
09

References and documents

Publications

  • Zhang X, Xu H, Zhang Z, Li Y, Pauer L, Liao S, Zhang F. Efficacy and Safety of Pregabalin for Fibromyalgia in a Population of Chinese Subjects. J Pain Res. 2021 Feb 25;14:537-548. doi: 10.2147/JPR.S281483. eCollection 2021. PubMed 33658841 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2012 to primary completion in Oct 2016, 56 months.

Results were first posted in Jul 2018, 1 year 8 months after primary completion.

Of 17 phase 3 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 56 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2011
First posted
Jul 4, 2011
StartActual
Feb 6, 2012
Primary completionActual
Oct 31, 2016
CompletionActual
Oct 31, 2016
Results first posted
Jul 30, 2018
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01387607
Responsible party
Sponsor
First posted
Jul 4, 2011
Start date
Feb 6, 2012
Primary completion
Oct 31, 2016
Completion
Oct 31, 2016
Results posted
Jul 30, 2018
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion